Mass General

This Week in Nature

In Nature this week: genomic factors that influence glioblastoma response to anti-PD-1 therapy, sequencing test for infectious disease, and more.

The team engineered an enhanced Acidaminococcus sp. Cas12a variant that has the ability to target many previously inaccessible protospacer adjacent motifs.

The article argues that PRS are bad at identifying those who will develop disease but others say this is the same for widely used risk factors.

The researchers believe using cerebral spinal fluid will enable them to identify brain tumors with a higher sensitivity than with blood samples.

BabySeq Project researchers reported that genomic sequencing could find even healthy newborns who are at risk of developing childhood-onset conditions.

Genome-wide association and meta-analyses have uncovered a dozen ADHD-related loci, providing insights into its biology and overlap with other conditions.

The projects are organized by the Eliminate Cancer Initiative, the National Brain Tumor Society, and the Pediatric Brain Tumor Foundation.

A Score for That

Nature News looks into the debates surrounding polygenic risk scores.

Classifying diabetes patients by genetic pathways may help improve their management, the researchers concluded.

The international team then used the approach to show that appropriate guide RNA design can reduce off-target effects of editing in mouse livers.

Pages

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.